
ECBF joins Novo Seeds and Sofinnova Partners in EUR11.5m round in Biosyntia
Using cutting-edge biotechnology and proprietary R&D tools and insights, the company is developing first-of-its-kind precision fermentation...

Orphan drug developer Minoryx raises €51m
The Series C round was co-led by Columbus Venture Partners and Caixa Capital Risc, and supported by CDTI Innvierte, Fund+, Ysios Capital and other...

French ImCheck get´s a USD103m check by Pfizer and a pack of VCs
With around EUR100m in previous financing rounds ImCheck’s financial position looks 'solidified' to take on the leadership in the gamma-delta T cell...

Polpharma Biologics Announces EMA Acceptance for Proposed Biosimilar Natalizumab (Tysabri)
Biosimilar natalizumab was developed by scientists at Polpharma Biologics (Poland) and the company retains responsibility for the manufacturing and...

Agomab extenses Series B with USD40m Bringing Total Amount to USD114m
Agomab is translating growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore...

Abliva decides on a SEK200m financing to fund Phase 2/3 study
Swedish Abliva is focussing on mitochondrial medicine, developing therapeutics for primary mitochondrial diseases, orphan indications of high unmet...

GSK splits off consumer health as Haleon - first stock listing today
Glaxo's consumer healthcare business is currently a joint venture between GSK, which owns 68% and Pfizer (PFE), which has 32%. The demerger...